Publications providing insights into the pathophysiology of, and therapeutic strategies for, EPS are the focus of the present review. Referenced publications are limited to those written in English.
BuckeR.C., SeabridgeC.E.The effect of chlorhexidine in the peritoneal cavity; an experimental study.Lancet1963; ii: 193–4.
2.
FooK.T., NgK.C., RauffA., FoongW.C., SinniahR.Unusual small intestinal obstruction in adolescent girls: The abdominal cocoon.Br J Surg1978; 65: 427–30.
3.
BrownP., BaddeleyH., ReadA.E., DaviesJ.D., McGarryJ.Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol).Lancet1974; 2: 1477–81.
4.
MarshallA.J., BaddeleyH., BarrittD.W., DaviesJ.D., LeeR.E., Low–BeerT.S.Practolol peritonitis. A study of 16 cases and a survey of small bowel function in patients taking beta adrenergic blockers.Q J Med1977; 46: 135–49.
5.
ThompsonR.P., JacksonB.T.Sclerosing peritonitis due to practolol.Br Med J1977; 1: 1393–4.
6.
HartyR.F.Sclerosing peritonitis and propranolol.Arch Intern Med1978; 138: 1424–6.
7.
GandhiV.C., HumayunH.M., IngT.S., DaugirdasJ.T., JablokowV.R., IwatsukiS.Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients.Arch Intern Med1980; 140: 1201–3.
SlingeneyerA., MionC., MouradG., CanaudB., FallerB., BeraudJ.J.Progressive sclerosing peritonitis: A late and severe complication of maintenance peritoneal dialysis.Trans Am Soc Artif Intern Organs1983; 29: 633–40.
10.
ShaldonS., KochK.M., QuellhorstE., DinarelloC.A.Pathogenesis of sclerosing peritonitis in CAPD.Trans Am Soc Artif Intern Organs1984; 30: 193–4.
11.
PedersenF.B., RyttovN., DeleuranP., DragsholtC., KildebergP.Acetate versus lactate in peritoneal dialysis solutions.Nephron1985; 39: 55–8.
12.
RottembourgJ., IssadB., LangloisP., TranbalocR., AdamouA., DeGrocF.Loss of ultrafiltration and sclerosing encapsulating peritonitis during CAPD: Evaluation of the potential risk factors.Adv CAPD1985; 1: 109–17.
13.
DobbieJ.W., HendersonI., WilsonL.S.New evidence on the pathogenesis of sclerosing encapsulating peritonitis (SEP) obtained from serial biopsies.Adv CAPD1987; 3: 138–49.
14.
PusateriR., RossR., MarshallR., MeredithJ.H., HamiltonR.W.Sclerosing encapsulating peritonitis: Report of a case with small bowel obstruction managed by long-term home parenteral hyperalimentation, and a review of the literature.Am J Kidney Dis1986; 8: 56–60.
15.
SlingeneyerA.Preliminary report on a cooperative international study on sclerosing encapsulating peritonitis.Contrib Nephrol1987; 57: 239–47.
16.
MackowR.C., ArgyW.P., WinchesterJ.F., RakowskiT.A., FieldsP.A., RotellarC.Sclerosing encapsulating peritonitis in rats induced by long-term intraperitoneal administration of antiseptics.J Lab Clin Med1988; 112: 363–71.
17.
OulesR., ChallahS., BrunnerF.P.Case-control study to determine the cause of sclerosing peritoneal disease.Nephrol Dial Transplant1988; 3: 66–9.
18.
KorzetsA., KorzetsZ., PeerG., PapoJ., SternD., BernheimJ.Sclerosing peritonitis. Possible early diagnosis by computerized tomography of the abdomen.Am J Nephrol1988; 8: 143–6.
KumanoK., ShimodaM., HyodoT., SakaiT.The role of TGF-β in growth inhibition of peritoneal mesothelial cells in high-glucose dialysate.Perit Dial Int1995; 15(Suppl): S93–5.
McLaughlinK., ButtG., MadiA., McMillanM., MactierR.Sclerosing peritonitis occurring in a hemodialysis patient.Am J Kidney Dis1996; 27: 729–32.
33.
NomotoY., KawaguchiY., KuboH., HiranoH., SakaiS., KurokawaK.Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: A report of the Japanese Sclerosing Encapsulating Peritonitis Study Group.Am J Kidney Dis1996; 28: 420–7.
34.
HendriksP.M., Ho-dac-PannekeetM.M., van GulikT.M., StruijkD.G., PhoaS.S., SieL.Peritoneal sclerosis in chronic peritoneal dialysis patients: Analysis of clinical presentation, risk factors, and peritoneal transport kinetics.Perit Dial Int1997; 17: 136–43.
35.
MoriY., MatsuoS., SutohH., ToriyamaT., KawaharaH., HottaN.A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone.Am J Kidney Dis1997; 30: 275–8.
36.
RougierJ.P., MoullierP., PiedagnelR., RoncoP.M.Hyperosmolality suppresses but TGF β 1 increases MMP9 in human peritoneal mesothelial cells.Kidney Int1997; 51: 337–47.
Ho-dac-PannekeetM.M., HiralallJ.K., StruijkD.G., KredietR.T.Longitudinal follow up of CA125 in peritoneal effluent.Kidney Int1997; 51: 888–93.
39.
RigbyR.J., HawleyC.M.Sclerosing peritonitis: The experience in Australia.Nephrol Dial Transplant1998; 13: 154–9.
40.
YamamotoT., IzumotaniT., OtoshiT., KimM.Morphological studies of mesothelial cells in CAPD effluent and their clinical significance.Am J Kidney Dis1998; 32: 946–52.
41.
MateijsenM.A., van der WalA.C., HendriksP.M., ZweersM.M., MulderJ., StruijkD.G.Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis.Perit Dial Int1999; 19: 517–25.
42.
ZweersM.M., de WaartD.R., SmitW., StruijkD.G., KredietR.T.Growth factors VEGF and TGF-β1 in peritoneal dialysis.J Lab Clin Med1999; 134: 124–32.
43.
YamagataK., TomidaC., KoyamaA.Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients.Perit Dial Int1999; 19: 131–7.
KawanishiH. for the Long-Term Peritoneal Dialysis Study Group. Encapsulating peritoneal sclerosis in Japan: Prospective multicenter controlled study.Perit Dial Int2001; 21(Suppl 3): S67–71.
46.
PollockC.A.Diagnosis and management of encapsulating peritoneal sclerosis.Perit Dial Int2001; 21(Suppl 3): S61–6.
47.
KawaguchiY., IshizukaT., ImadaA., OohiraS., KuriyamaS., NakamotoH.Searching for the reasons for drop-out from peritoneal dialysis: A nation-wide survey in Japan.Perit Dial Int2003; 23(Suppl 2): S175–7.
48.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R., for the Peritoneal Biopsy Study Group. Morphological changes in the peritoneal membrane of patients with renal disease.J Am Soc Nephrol2002; 13: 470–9.
49.
DevuystO.New insights in the molecular mechanisms regulating peritoneal permeability.Nephrol Dial Transplant2002; 17: 548–51.
50.
MoellerS., GiobergeS., BrownG.ESRD patients in 2001: Global overview of patients, treatment modalities and development trends.Nephrol Dial Transplant2002; 17: 2071–6.
